Newron Pharmaceuticals Management
Management criteria checks 3/4
Newron Pharmaceuticals' CEO is Stefan Weber, appointed in Jun 2012, has a tenure of 12.5 years. total yearly compensation is €510.00K, comprised of 93.1% salary and 6.9% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth €184.58K. The average tenure of the management team and the board of directors is 12.5 years and 12.9 years respectively.
Key information
Stefan Weber
Chief executive officer
€510.0k
Total compensation
| CEO salary percentage | 93.1% |
| CEO tenure | 12.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 12.5yrs |
| Board average tenure | 12.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€19m |
| Mar 31 2024 | n/a | n/a | -€18m |
| Dec 31 2023 | €510k | €475k | -€16m |
| Sep 30 2023 | n/a | n/a | -€16m |
| Jun 30 2023 | n/a | n/a | -€16m |
| Mar 31 2023 | n/a | n/a | -€17m |
| Dec 31 2022 | €498k | €429k | -€17m |
| Sep 30 2022 | n/a | n/a | -€16m |
| Jun 30 2022 | n/a | n/a | -€14m |
| Mar 31 2022 | n/a | n/a | -€15m |
| Dec 31 2021 | €510k | €414k | -€15m |
| Sep 30 2021 | n/a | n/a | -€17m |
| Jun 30 2021 | n/a | n/a | -€20m |
| Mar 31 2021 | n/a | n/a | -€20m |
| Dec 31 2020 | €582k | €403k | -€21m |
| Sep 30 2020 | n/a | n/a | -€19m |
| Jun 30 2020 | n/a | n/a | -€17m |
| Mar 31 2020 | n/a | n/a | -€18m |
| Dec 31 2019 | €691k | €440k | -€20m |
| Sep 30 2019 | n/a | n/a | -€21m |
| Jun 30 2019 | n/a | n/a | -€21m |
| Mar 31 2019 | n/a | n/a | -€18m |
| Dec 31 2018 | €647k | €430k | -€15m |
| Sep 30 2018 | n/a | n/a | -€15m |
| Jun 30 2018 | n/a | n/a | -€14m |
| Mar 31 2018 | n/a | n/a | -€10m |
| Dec 31 2017 | €563k | €418k | -€5m |
Compensation vs Market: Stefan's total compensation ($USD530.20K) is below average for companies of similar size in the German market ($USD900.01K).
Compensation vs Earnings: Stefan's compensation has increased whilst the company is unprofitable.
CEO
Stefan Weber (59 yo)
12.5yrs
Tenure
€510,000
Compensation
Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 12.5yrs | €510.00k | 0.10% € 184.6k | |
| Chief Financial Officer | 12.5yrs | no data | 0.013% € 22.7k | |
| Vice President of Operations | 2.4yrs | no data | no data | |
| Chief Medical Officer | 19.6yrs | €1.12m | 0.22% € 379.8k | |
| Vice President of Business Development | 1.4yrs | no data | no data |
12.5yrs
Average Tenure
Experienced Management: NP5's management team is seasoned and experienced (12.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 12.9yrs | €510.00k | 0.10% € 184.6k | |
| Independent Non-Executive Director | 16.4yrs | €78.00k | 0.062% € 108.8k | |
| Independent Non-Executive Chairman | 11.7yrs | €106.00k | 0.21% € 365.1k | |
| Non-Executive & Independent Director | 10.8yrs | €68.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of the Board of Statutory Auditors | 22.9yrs | €13.00k | no data |
12.9yrs
Average Tenure
63yo
Average Age
Experienced Board: NP5's board of directors are seasoned and experienced ( 12.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 06:21 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Newron Pharmaceuticals S.p.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |